Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
76 participants
OBSERVATIONAL
2007-03-31
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* It has been a tendency that a blood based cardioplegia gives a better protection bye long ischemic times but it has not been possible too conclude in this matter.
* The investigators have two groups of cardioplegia, the blood based and, the crystalloid based cardioplegia.
* It has been done a lot of studies to see what kind of cardioplegia that gives the best myocardial protection. Different temperature, different amount and content, retrograde or antegrade or both, contentiously and further on have been tested without a clear conclusion.
* The investigators decided to make a study with a cohort of patients as homogenous as possible with a cross clamp time around 70 min.
* Adult patients' with a severe aortic stenoses without any other significant heart disease was included in our prospective randomised study.
* Patients with additional significant coronary artery disease (≥ 50% stenoses) were excluded from the study.
* The investigators used the well known biomarkers CK-MB and troponin-T too evaluate the myocardial damage.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods: 100 patients with aorta stenoses undergoing aortic valve replacement without significant coronary artery stenoses or other significant concomitant heart valve disease were included in the study. They were given antegrade cold blood or cold crystalloid cardioplegia delivered through the coronary Ostia every 20 min throughout the period of aortic cross-clamp. CK-MB and troponin-T were compared between the two groups.
Published 2010 in the journal of thoracic and cardiovascular surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1 Custodiol
Custodiol
No interventions assigned to this group
2 Blood cardioplegia
Blood cardioplegia
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with mitral regurgitation equal to or larger than grade 3 out of 4.
* Ablation for atrial fibrillation was the only concomitant procedure that was allowed in addition to mitral valve surgery and these patients were block-randomized to ensure equally many patients with ablation in the two groups of cardioplegia.
Exclusion Criteria
* Age below 18
* Pregnant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ullevaal University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bjørn Braathen
MD. Ph.D
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Theis Tønnessen, prof.dr.med
Role: STUDY_DIRECTOR
Thoraxkirurgisk avd. UUS
Bjørn Braathen, med.doc
Role: STUDY_CHAIR
Thoraxkir.avd. UUS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
thoraxkirurgisk avd, UUS
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-001780-30
Identifier Type: -
Identifier Source: org_study_id